202 related articles for article (PubMed ID: 25616902)
21. Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety.
Moreau P; Anizon F; Giraud F; Esvan YJ
Recent Pat Anticancer Drug Discov; 2016; 11(3):309-21. PubMed ID: 27194556
[TBL] [Abstract][Full Text] [Related]
22. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
[TBL] [Abstract][Full Text] [Related]
23. Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
Quevedo CE; Bataille CJR; Byrne S; Durbin M; Elkins J; Guillermo A; Jones AM; Knapp S; Nadali A; Walker RG; Wilkinson IVL; Wynne GM; Davies SG; Russell AJ
Bioorg Med Chem; 2020 Nov; 28(22):115724. PubMed ID: 33128909
[TBL] [Abstract][Full Text] [Related]
24. A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors.
Schulz MN; Fanghänel J; Schäfer M; Badock V; Briem H; Boemer U; Nguyen D; Husemann M; Hillig RC
Acta Crystallogr D Biol Crystallogr; 2011 Mar; 67(Pt 3):156-66. PubMed ID: 21358046
[TBL] [Abstract][Full Text] [Related]
25. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
[TBL] [Abstract][Full Text] [Related]
26. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
[TBL] [Abstract][Full Text] [Related]
27. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
Qian K; Wang L; Cywin CL; Farmer BT; Hickey E; Homon C; Jakes S; Kashem MA; Lee G; Leonard S; Li J; Magboo R; Mao W; Pack E; Peng C; Prokopowicz A; Welzel M; Wolak J; Morwick T
J Med Chem; 2009 Apr; 52(7):1814-27. PubMed ID: 19256503
[TBL] [Abstract][Full Text] [Related]
28. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaële D
Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
[TBL] [Abstract][Full Text] [Related]
29. Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.
Pastor J; Oyarzabal J; Saluste G; Alvarez RM; Rivero V; Ramos F; Cendón E; Blanco-Aparicio C; Ajenjo N; Cebriá A; Albarrán MI; Cebrián D; Corrionero A; Fominaya J; Montoya G; Mazzorana M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1591-7. PubMed ID: 22266039
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases.
Nishiguchi GA; Atallah G; Bellamacina C; Burger MT; Ding Y; Feucht PH; Garcia PD; Han W; Klivansky L; Lindvall M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6366-9. PubMed ID: 21945284
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.
Shahin R; Swellmeen L; Shaheen O; Aboalhaija N; Habash M
J Comput Aided Mol Des; 2016 Jan; 30(1):39-68. PubMed ID: 26685860
[TBL] [Abstract][Full Text] [Related]
33. PIM kinase inhibitors: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2019 Jun; 172():95-108. PubMed ID: 30954777
[TBL] [Abstract][Full Text] [Related]
34. Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1.
Ekambaram R; Enkvist E; Vaasa A; Kasari M; Raidaru G; Knapp S; Uri A
ChemMedChem; 2013 Jun; 8(6):909-13. PubMed ID: 23616352
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.
Dakin LA; Block MH; Chen H; Code E; Dowling JE; Feng X; Ferguson AD; Green I; Hird AW; Howard T; Keeton EK; Lamb ML; Lyne PD; Pollard H; Read J; Wu AJ; Zhang T; Zheng X
Bioorg Med Chem Lett; 2012 Jul; 22(14):4599-604. PubMed ID: 22727640
[TBL] [Abstract][Full Text] [Related]
36. Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors - Lead optimization - Part III.
Barberis C; Pribish J; Tserlin E; Gross A; Czekaj M; Barragué M; Erdman P; Maniar S; Jiang J; Fire L; Patel V; Hebert A; Levit M; Wang A; Sun F; Huang SA
Bioorg Med Chem Lett; 2019 Feb; 29(3):491-495. PubMed ID: 30553737
[TBL] [Abstract][Full Text] [Related]
37. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking.
Ren JX; Li LL; Zheng RL; Xie HZ; Cao ZX; Feng S; Pan YL; Chen X; Wei YQ; Yang SY
J Chem Inf Model; 2011 Jun; 51(6):1364-75. PubMed ID: 21618971
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold.
Nishiguchi GA; Burger MT; Han W; Lan J; Atallah G; Tamez V; Lindvall M; Bellamacina C; Garcia P; Feucht P; Zavorotinskaya T; Dai Y; Wong K
Bioorg Med Chem Lett; 2016 May; 26(9):2328-32. PubMed ID: 26995528
[TBL] [Abstract][Full Text] [Related]
40. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
Bataille CJ; Brennan MB; Byrne S; Davies SG; Durbin M; Fedorov O; Huber KV; Jones AM; Knapp S; Liu G; Nadali A; Quevedo CE; Russell AJ; Walker RG; Westwood R; Wynne GM
Bioorg Med Chem; 2017 May; 25(9):2657-2665. PubMed ID: 28341403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
